Pembrolizumab vs Sugemalimab

## Pembrolizumab vs Sugemalimab: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Sugemalimab**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Sugemalimab — N/A.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Sugemalimab — Antibody.